<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="18%"></col>
<col width="82%"></col>
<tbody>
<tr>
<td colspan="2" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Drugs That Interfere with Hemostasis</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="unordered">
<item>Celecoxib and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of celecoxib and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.
           </item>
<item>Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.
           </item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Monitor patients with concomitant use of celecoxib with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [
           
     
      <content stylecode="italics">see Warnings and Precautions (
            
      
       <content stylecode="underline">
<linkhtml href="#i4i_section_id_5a6ea689-c7a0-4745-8ed8-605a0e6d138b">5.11</linkhtml>
</content>)
           
     
      </content>].
          
    
     </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Aspirin</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [
           
     
      <content stylecode="italics">see Warnings and Precautions (
            
      
       <content stylecode="underline">
<linkhtml href="#i4i_section_id_af2863b8-44c7-4a25-a560-23a3790c8a5d">5.2</linkhtml>
</content>)
           
     
      </content>].
           
     
      <br/>In two studies in healthy volunteers, and in patients with osteoarthritis and established heart disease respectively, celecoxib (200 to 400 mg daily) has demonstrated a lack of interference with the cardioprotective antiplatelet effect of aspirin (100 to 325 mg).
          
    
     </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Concomitant use of celecoxib and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [
           
     
      <content stylecode="italics">see Warnings and Precautions (
            
      
       <content stylecode="underline">
<linkhtml href="#i4i_section_id_5a6ea689-c7a0-4745-8ed8-605a0e6d138b">5.11</linkhtml>
</content>)
           
     
      </content>].
           
     
      <br/>Celecoxib is not a substitute for low dose aspirin for cardiovascular protection.
          
    
     </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="unordered">
<item>NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol).
           </item>
<item>In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, coadministration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.
           </item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<list listtype="unordered">
<item>During concomitant use of celecoxib and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained.
           </item>
<item>During concomitant use of celecoxib and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [
            
      
       <content stylecode="italics">see Warnings and Precautions (
             
       
        <content stylecode="underline">
<linkhtml href="#i4i_section_id_2b433356-fca9-4de7-b061-b3d3ff6c2f94">5.6</linkhtml>
</content>)
            
      
       </content>].
           
     
      </item>
<item>When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter.
           </item>
</list>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Diuretics</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Clinical studies, as well as postmarketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>During concomitant use of celecoxib with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [
           
     
      <content stylecode="italics">see Warnings and Precautions (
            
      
       <content stylecode="underline">
<linkhtml href="#i4i_section_id_2b433356-fca9-4de7-b061-b3d3ff6c2f94">5.6</linkhtml>
</content>)
           
     
      </content>].
          
    
     </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Digoxin</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>The concomitant use of Celecoxib with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>During concomitant use of celecoxib and digoxin, monitor serum digoxin levels.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Lithium</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>During concomitant use of celecoxib and lithium, monitor patients for signs of lithium toxicity.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Methotrexate</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction).</paragraph>
<paragraph>Celecoxib has no effect on methotrexate pharmacokinetics.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>During concomitant use of celecoxib and methotrexate, monitor patients for methotrexate toxicity.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Cyclosporine</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Concomitant use of celecoxib and cyclosporine may increase cyclosporineâ€™s nephrotoxicity.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>During concomitant use of celecoxib and cyclosporine, monitor patients for signs of worsening renal function.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">NSAIDs and Salicylates</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Concomitant use of Celecoxib with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [
           
     
      <content stylecode="italics">see Warnings and Precautions (
            
      
       <content stylecode="underline">
<linkhtml href="#i4i_section_id_af2863b8-44c7-4a25-a560-23a3790c8a5d">5.2</linkhtml>
</content>)
           
     
      </content>].
          
    
     </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>The concomitant use of Celecoxib with other NSAIDs or salicylates is not recommended.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Pemetrexed</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Concomitant use of celecoxib and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>During concomitant use of celecoxib and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. 
           
     
      <br/>NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed.
           
     
      <br/>In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.
          
    
     </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">CYP2C9 Inhibitors or inducers</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Celecoxib metabolism is predominantly mediated via cytochrome P450 (CYP) 2C9 in the liver. Coadministration of celecoxib with drugs that are known to inhibit CYP2C9 (e.g. fluconazole) may enhance the exposure and toxicity of celecoxib whereas coadministration with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of celecoxib.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Evaluate each patient's medical history when consideration is given to prescribing celecoxib. A dosage adjustment may be warranted when celecoxib is administered with CYP2C9 inhibitors or inducers [
           
     
      <content stylecode="italics">see Clinical Pharmacology (
            
      
       <content stylecode="underline">
<linkhtml href="#i4i_pharmacokinetics_id_c6174af6-fb12-4db1-93c0-460747d42286">12.3</linkhtml>
</content>)
           
     
      </content>].
          
    
     </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">CYP2D6 substrates</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">In vitro</content> studies indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6. Therefore, there is a potential for an 
           
     
      <content stylecode="italics">in vivo</content> drug interaction with drugs that are metabolized by CYP2D6 (e.g. atomoxetine), and celecoxib may enhance the exposure and toxicity of these drugs.
          
    
     </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Evaluate each patient's medical history when consideration is given to prescribing celecoxib. A dosage adjustment may be warranted when celecoxib is administered with CYP2D6 substrates [
           
     
      <content stylecode="italics">see Clinical Pharmacology (
            
      
       <content stylecode="underline">
<linkhtml href="#i4i_pharmacokinetics_id_c6174af6-fb12-4db1-93c0-460747d42286">12.3</linkhtml>
</content>)
           
     
      </content>]. 
          
    
     </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Corticosteroids</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Concomitant use of corticosteroids with celecoxib may increase the risk of GI ulceration or bleeding. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>Monitor patients with concomitant use of celecoxib with corticosteroids for signs of bleeding [
           
     
      <content stylecode="italics">see Warnings and Precautions (
            
      
       <content stylecode="underline">
<linkhtml href="#i4i_section_id_af2863b8-44c7-4a25-a560-23a3790c8a5d">5.2</linkhtml>
</content>)
           
     
      </content>]. 
          
    
     </paragraph>
</td>
</tr>
</tbody>
</table>